GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (NSE:AKUMS) » Definitions » Capex-to-Operating-Income

Akums Drugs and Pharmaceuticals (NSE:AKUMS) Capex-to-Operating-Income : 0.85 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Akums Drugs and Pharmaceuticals's Capital Expenditure for the six months ended in Sep. 2024 was ₹-1,503.62 Mil. Its Operating Income for the six months ended in Sep. 2024 was ₹1,764.06 Mil.

Hence, Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income for the six months ended in Sep. 2024 was 0.85.

Akums Drugs and Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals Capex-to-Operating-Income Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Capex-to-Operating-Income
0.36 0.80 1.72 0.87

Akums Drugs and Pharmaceuticals Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Capex-to-Operating-Income Get a 7-Day Free Trial 3.84 0.85 0.63 1.24 0.85

Competitive Comparison of Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income falls into.


Akums Drugs and Pharmaceuticals Capex-to-Operating-Income Calculation

Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-3114.08) / 3598.99
=0.87

Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1503.62) / 1764.06
=0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals  (NSE:AKUMS) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Akums Drugs and Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Akums Drugs and Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (NSE:AKUMS) » Definitions » Capex-to-Operating-Income
Comparable Companies
BOM:524372 BOM:500126 BOM:543322 BOM:531599 BOM:530549 BOM:532872 BOM:532482 NSE:STAR NSE:INNOVACAP BOM:543748 ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
544222:India
Address
Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Website
https://www.akums.in
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines